Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell TAK and other ETFs, options, and stocks.

About TAK

Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. It operates through the following business divisions: Gastrointestinal Diseases, Rare Diseases, Plasma-Derived Therapies, Oncology, Vaccines, and Neuroscience The company was founded by Takeda Chobei on June 12, 1781 and is headquartered in Osaka, Japan. 

CEO
Julie So-Young Kim
CEOJulie So-Young Kim
Employees
47,029
Employees47,029
Headquarters
Osaka, Osaka
HeadquartersOsaka, Osaka
Founded
1781
Founded1781
Employees
47,029
Employees47,029

TAK Key Statistics

Market cap
57.33B
Market cap57.33B
Price-Earnings ratio
-60.80
Price-Earnings ratio-60.80
Dividend yield
3.63%
Dividend yield3.63%
Average volume
4.37M
Average volume4.37M
High today
$17.19
High today$17.19
Low today
$16.93
Low today$16.93
Open price
$17.19
Open price$17.19
Volume
4.11M
Volume4.11M
52 Week high
$18.90
52 Week high$18.90
52 Week low
$12.99
52 Week low$12.99

TAK News

Simply Wall St 1d
Takeda Stock Struggles To Convert Revenue Growth Into Lasting Profit - simplywall.st

...

Takeda Stock Struggles To Convert Revenue Growth Into Lasting Profit - simplywall.st
TipRanks 1d
Takeda Tracks Real World Safety of Ceprotin (TAK-662) in Rare Clotting Disorder

Takeda Pharmaceutical Company (TAK) announced an update on their ongoing clinical study. Unlock powerful investing tools with TipRanks Premium to make smarter,...

TipRanks 2d
Keros Therapeutics to receive $20M elritercept milestone payment from Takeda

Keros Therapeutics (KROS) announced that it will receive a $20M development milestone payment under the terms of the license agreement of elritercept with partn...

Analyst ratings

56%

of 16 ratings
Buy
56.3%
Hold
43.8%
Sell
0%

More TAK News

TipRanks 3d
Mamegano Reiterates Buy on Takeda as Q1 Beat and Pipeline Progress Support Unchanged Price Objective

Koichi Mamegano, an analyst from Bank of America Securities, maintained the Buy rating on Takeda Pharmaceutical Co. The associated price target is Yen6,000.00....

TipRanks 3d
Takeda Delivers Strong Q1 Revenue Growth But Flags Core EPS Decline

Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions Subscribe to TipRanks Smart Investor Newsletter, and...

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.